Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 3/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.34 |
| ▸ | CYP26B1 | Q9NR63 | 4/20 | 0.34 |
| ▸ | RARA | P10276 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.34 |
| ▸ | RARG | P13631 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619134 | 0.78 | RXRA (0.53) | RXRARXRBGAARXRGCYP26A1 | |
| SCHEMBL1619138 | 0.77 | RXRA (0.39) | RXRARXRBGAAEPHX2DDB1 | |
| SCHEMBL20189877 | 0.76 | GAA (0.44) | GAAEPHX2DDB1CRBNHDAC6 | |
| SCHEMBL1618995 | 0.75 | POLB (0.60) | RXRARXRBGAARXRGHDAC6 | |
| SCHEMBL20189726 | 0.74 | GAA (0.43) | GAAEPHX2DDB1CRBNHDAC6 | |
| SCHEMBL5493302 | 0.73 | RARG (0.51) | RXRAGAARARARARBRARG | |
| SCHEMBL14492785 | 0.71 | RXRA (0.53) | RXRARXRBPPARGALDH1A1 | |
| SCHEMBL14492799 | 0.71 | RXRA (0.50) | RXRARXRBRXRGCYP26A1CYP26B1 | |
| SCHEMBL1619115 | 0.70 | RXRA (0.55) | RXRARXRBGAAEPHX2DDB1 | |
| SCHEMBL14492787 | 0.70 | CA2 (0.53) | RXRARXRBRXRGPPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392326-B1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL JANSSEN PHARM (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | BUSSOLARI JACQUELINE C | 2009-03-19 | — | — | US | claimed |
| US-6838442-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-01-04 | — | — | US | claimed |
| EP-1392326-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | Ortho McNeil Pharmaceutical, Inc. (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | BUSSOLARI JACQUELINE C (US) | 2003-10-16 | — | — | US | claimed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-8796313-B2 | Substituted dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-08-05 | — | — | US | disclosed |
| US-8680122-B2 | Substituted pyrrolones as allosteric modulators of glucokinase | JANSSEN PHARMACETICA N.V. (BE) | 2014-03-25 | — | — | US | disclosed |
| US-8236819-B2 | Dihydro-[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-07 | — | — | US | disclosed |
| US-8183213-B2 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-7928246-B2 | Dihydroisoindolones as allosteric modulators of glucokinase | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| WO-2002080935-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055091-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885RXRB 9/4885GAA 250/4885 |
| US-20030195235-A1 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885RXRB 9/4885GAA 250/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | RXRA 247/4885RXRB 232/4885GAA 1680/4885 |
| US-20090075864-A1 | COMBINATION THERAPY COMPRISING GLUCOSE REABSORPTION INHIBITORS AND RETINOID-X RECEPTOR MODULATORS | GPR119, SLC2A4, SLC2A1 | RXRA 11/4885RXRB 9/4885GAA 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.